---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-26-000059"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2026-05-12T20:01:42+00:00"
generated_at: "2026-05-12T21:37:52.806449+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Curis Q1 net loss $24.2M, no revenue; cash $15M; clinical milestones ahead

## Summary
- Net loss of $24.2M ($1.25 per share) vs $10.6M loss in Q1 2025; EPS unchanged due to higher share count.
- No revenue in Q1 2026 after sale of Erivedge royalties in Q4 2025; Q1 2025 had $2.4M royalty revenue.
- Cash and equivalents $15.0M as of Mar 31; expects runway into H2 2027 contingent on $20.2M Series B warrant exercise.
- Closed $80.8M private placement in Jan 2026; initial $20.2M received; warrants exercisable at $0.75 per share.
- TakeAim CLL combination trial with zanubrutinib expects dosing of 5th patient mid-2026; PCNSL data in 1H 2027.

## SEC filing metadata
- accession: 0001108205-26-000059
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2026-05-12T20:01:42+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/0001108205-26-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/cris-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-26-000059
- JSON: https://secwatch.observer/filing/0001108205-26-000059.json
- Plain text: https://secwatch.observer/filing/0001108205-26-000059.txt

## Key facts
- Earnings Releases
  CURIS INC reported for the quarter ended March 31, 2026 results: net income net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis, EPS $1.25 per share on both a basic and diluted basis.
  - Period: for the quarter ended March 31, 2026
  - Net income: net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis
  - EPS: $1.25 per share on both a basic and diluted basis
  - Result: reported results
  source text: On May 12, 2026, Curis, Inc. announced its financial results for the three-month periods ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/0001108205-26-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.